• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Cinnamic acids and derivatives Coumaric acids and derivatives
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides Cinnamic acids and derivatives Hydroxycinnamic acids and derivatives Coumaric acids and derivatives

Recent Advances in p-Coumaroyltyramine (20375-37-5) Research: A Comprehensive Review

p-Coumaroyltyramine (CAS: 20375-37-5) is a naturally occurring phenolic amide that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its diverse biological activities. Recent studies have explored its potential as an anti-inflammatory, antioxidant, and anticancer agent, making it a promising candidate for therapeutic development. This research brief aims to synthesize the latest findings on p-Coumaroyltyramine, focusing on its molecular mechanisms, pharmacological effects, and potential applications in medicine.

One of the most notable advancements in p-Coumaroyltyramine research is its role in modulating inflammatory pathways. A 2023 study published in the *Journal of Natural Products* demonstrated that p-Coumaroyltyramine significantly inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophages. The study utilized a combination of in vitro assays and molecular docking simulations to elucidate the compound's interaction with key inflammatory mediators. These findings suggest that p-Coumaroyltyramine could serve as a lead compound for developing novel anti-inflammatory drugs.

In addition to its anti-inflammatory properties, p-Coumaroyltyramine has shown remarkable antioxidant activity. Research conducted by a team at the University of California, Davis, revealed that the compound effectively scavenges free radicals and reduces oxidative stress in neuronal cells. This study, published in *Free Radical Biology and Medicine*, employed advanced techniques such as electron paramagnetic resonance (EPR) spectroscopy to quantify the compound's radical-scavenging capacity. The results highlight p-Coumaroyltyramine's potential in treating neurodegenerative diseases associated with oxidative damage.

Another groundbreaking study, published in *Cancer Research* in early 2024, investigated the anticancer effects of p-Coumaroyltyramine. The research team found that the compound induces apoptosis in several cancer cell lines, including breast and colon cancer, by activating the intrinsic mitochondrial pathway. Furthermore, p-Coumaroyltyramine was shown to synergize with conventional chemotherapeutic agents, enhancing their efficacy while minimizing side effects. These findings open new avenues for combination therapies in oncology.

Despite these promising results, challenges remain in the clinical translation of p-Coumaroyltyramine. Issues such as bioavailability, metabolic stability, and targeted delivery need to be addressed to fully harness its therapeutic potential. Recent efforts in drug formulation, including the development of nanoparticle-based delivery systems, have shown promise in overcoming these hurdles. A 2023 study in *Advanced Drug Delivery Reviews* highlighted the use of lipid nanoparticles to improve the solubility and bioavailability of p-Coumaroyltyramine, paving the way for future clinical trials.

In conclusion, p-Coumaroyltyramine (20375-37-5) represents a multifaceted compound with significant therapeutic potential. Its anti-inflammatory, antioxidant, and anticancer properties, as evidenced by recent studies, position it as a valuable candidate for further drug development. Ongoing research into its molecular mechanisms and formulation strategies will be crucial in translating these findings into clinical applications. As the field progresses, p-Coumaroyltyramine may soon emerge as a cornerstone in the treatment of various chronic and degenerative diseases.

• 36417-86-4(N-p-trans-Coumaroyltyramine)
• 103188-46-1((E)-N-(3,4-Dihydroxyphenethyl)-3-(4-hydroxyphenyl)acrylamide)
• 103188-49-4((E)-N-(3,4-Dihydroxyphenethyl)-3-(3,4-dihydroxyphenyl)acrylamide)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)